Abstract 1305P
Background
For patients who show downstaging of lung cancer following targeted therapy, salvage surgery can be considered. Resection of regrowing pulmonary masses can also be performed to acquire a tumor specimen. The aim of this study is to evaluate the prognosis of patients who have undergone prior tyrosine kinase inhibitor (TKI) treatment and later lung surgery.
Methods
The deidentified data of NSCLC patients admitted to eight university hospitals affiliated with the Catholic University of Korea were obtained from the Clinical Data Warehouse (CDW) database. Forty patients who had prior targeted therapies and later received surgical resection were evaluated for the study. The primary endpoint was overall survival, defined as the time between surgical resection and death or censoring. The secondary endpoint was postoperative progression-free survival.
Results
Of 40 patients diagnosed with adenocarcinoma. 36 (87.8%) received prior EGFR TKI treatment, while 4 (9.8%) received ALK TKI treatment. At the time of TKI initiation, 31 (77.5%) were staged as IV, and 9 (22.5%) were staged as III. Salvage surgery was performed in 18 patients (45.0%), and 22 (55.0%) underwent resection for biopsy purposes. At the time of resection, tumor burden was unchanged in 7 patients (17.5%), significantly regressing in 12 patients (30.0%), and increasing in 21 patients (52.5%). Among the 28 patients with EGFR mutations from resected tumor specimens, 9 (32.1%) exhibited the T790M mutation. Next-generation sequencing of the resected samples identified mutations such as MET amplification and TP53. Only one postoperative complication, atrial fibrillation, was observed. Patients with poor preoperative ECOG (Eastern Cooperative Oncology Group) scores had significantly worse 1-year and 2-year survival rates (P=0.014 and P=0.011, respectively). There was a significant difference in 6-month PFS rates between groups stratified by pleural invasion levels (PL0-3) (P=0.029). Furthermore, patients with T790M mutation showed a trend towards improved PFS (P=0.052).
Conclusions
Lung surgery following targeted therapies is safe and can be used to predict the prognosis of patients with initially unresectable NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Presenter: Gretchen Kimmick
Session: Poster session 04
458P - Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
Presenter: Camilla Lisanti
Session: Poster session 04
460P - Impact of fulvestrant utilization on prognostic outcome among patients with HR+ve/HER2-ve metastatic breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 04
462P - Health outcomes of treatment sequences with eribulin or other single agents’ chemotherapy for treating relapsed metastatic HER2-negative breast cancer
Presenter: Simone Rivolo
Session: Poster session 04
463P - Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study
Presenter: Sonia Priou
Session: Poster session 04
464P - Developing a prognostic risk stratification model and treatment options for HER2-positive breast cancer brain metastasis
Presenter: JiaXin Chen
Session: Poster session 04
465P - Reporting of older subgroups enrolled to registration breast cancer trials, 2012-2021
Presenter: Colm Mac Eochagain
Session: Poster session 04